This information is intended only for healthcare professionals resident in the United Kingdom


Prescribing Information (PI) for Xeljanz ® (tofacitinib)
Adverse events should be reported. Reporting forms and information can be found at https://yellowcard.mhra.gov.uk/ or search
for MHRA Yellow Card in Google Play or Apple App Store

Adverse events should also be reported to Pfizer Medical Information on 01304 616161

Pfizer Ltd. accepts no responsibility for the content or services of the linked site other than the information relating to Pfizer medicines which it has provided or reviewed

United Kingdom 

  • Xeljanz (tofacitinib) 5mg film-coated tablets - PI for UK
  • Xeljanz (tofacitinib) 11mg prolonged release tablets - PI for UK
  • Xeljanz (tofacitinib) 10mg prolonged release tablets - PI for UK
  • Xeljanz (tofacitinib) 1mg/ml oral solution - PI for UK

Xeljanz (tofacitinib) 5mg film-coated tablets 

Xeljanz (tofacitinib) 11mg prolonged release tablets

Xeljanz (tofacitinib) 10mg film-coated tablets 

Xeljanz (tofacitinib) 1mg/ml Oral Solution 

PP-XEL-GBR-5179. April 2026